- What changed in GRAL news today?
- Grail rises as TD Cowen more than doubles price target on FDA, Medicare optimism: Grail shares rose more than 2% to $140.53 after TD Cowen raised its price target to $180 from $88 and kept its buy rating. The brokerage raised its estimated chance of FDA approval for Galleri to 95% from 75% and expects a decision in Q1 2027, as well as favorable Medicare coverage in H1 2028.
- Does Rallies summarize GRAL news?
- Yes. Rallies summarizes GRAL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is GRAL research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for GRAL. It does not provide personalized investment advice.
